Small-Molecule TREM-1 Antagonists for Longer-Lived Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for targeting the triggering receptor expressed on myeloid cells 1 (TREM-1) are limited, particularly in clinical settings, with peptide therapeutics having a short lifespan and targeting both TREM-1 and TLR-4 not being advantageous for many pathological conditions.
Innovation Solution
Development of small molecule TREM-1 antagonists, including compounds of Formulas I and II, which can inhibit TREM-1 activity and are formulated into pharmaceutical compositions for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide therapeutics are used to target TREM-1, then specific inhibition of TREM-1 can be achieved, but the therapeutic has a limited lifespan due to degradation
Solution Approach 1:
The patent transitions from peptide-based therapeutics to small molecule compounds, fundamentally changing the chemical parameter class from macromolecular peptides to low-molecular-weight compounds. This parameter change confers metabolic stability and extended lifespan while maintaining TREM-1 binding capability through rational drug design and structure-activity relationship studies
Solution Approach 2:
The patent replaces the short-lived peptide therapeutics with small molecule compounds that have extended circulation half-life and metabolic stability, effectively substituting a short-living therapeutic class with a long-living alternative that requires less frequent administration
2Adaptability or versatility
If both TREM-1 and TLR-4 are targeted, then broad anti-inflammatory effects can be achieved, but this is not advantageous for most clinical pathological conditions
Solution Approach 1:
The patent extracts and isolates the TREM-1 binding functionality from dual TREM-1/TLR-4 targeting approaches, creating compounds that specifically target only TREM-1. This selective targeting is achieved through molecular design that favors TREM-1 binding affinity and specificity, eliminating off-target TLR-4 effects that complicate clinical application
Solution Approach 2:
Instead of designing compounds that target both TREM-1 and TLR-4 (broad approach), the patent inverts the strategy by designing compounds that target exclusively TREM-1 (narrow approach), thereby simplifying the therapeutic profile and improving clinical applicability for specific pathological conditions
3Reliability
If TREM-1 blockers are developed for clinical use, then therapeutic benefits for inflammatory diseases can be achieved, but current options are limited to pre-clinical animal models
Solution Approach 1:
The patent performs preliminary actions by completing comprehensive pre-clinical characterization including in vitro mechanistic studies, in vivo efficacy models, and toxicology assessments before advancing to clinical trials. This thorough preliminary work package reduces uncertainties and accelerates the transition from pre-clinical to clinical settings
Solution Approach 2:
The patent replaces the experimental/academic development pathway with a structured pharmaceutical development pathway, transitioning from mechanistic studies in animal models to GMP-manufactured clinical-grade materials, thereby substituting research-mode development with industry-mode development to enable clinical translation
Data Source
AI summary
Provided herein are compounds of formula I or an enantiomer, solvate, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and medicaments that include the compounds described herein as well as methods of treating inflammatory disease, cardiovascular disease, and cancer.